Kiacta eprodisate: Completed Phase III enrollment

Auven completed enrollment of 230 patients in a double-blind, placebo-controlled, international Phase III trial of oral 400 mg Kiacta. Patients will receive 1-3 capsules of Kiacta twice daily and the dosing will be adjusted in accordance to CrCL level increases or decreases. The trial will conclude when 120 patients have experienced an event linked to deterioration of kidney function. As of May 27, >60 patients have had an event. ...